Stryker Co. (NYSE:SYK) Shares Sold by Resonant Capital Advisors LLC

Resonant Capital Advisors LLC decreased its holdings in Stryker Co. (NYSE:SYK) by 0.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,196 shares of the medical technology company’s stock after selling 51 shares during the period. Resonant Capital Advisors LLC’s holdings in Stryker were worth $3,319,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of SYK. Dunhill Financial LLC lifted its stake in Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 37 shares during the last quarter. Darwin Wealth Management LLC purchased a new stake in Stryker during the third quarter worth approximately $36,000. Crews Bank & Trust purchased a new stake in Stryker during the fourth quarter worth approximately $39,000. HBW Advisory Services LLC purchased a new stake in Stryker during the third quarter worth approximately $42,000. Finally, Hara Capital LLC purchased a new stake in Stryker during the third quarter worth approximately $42,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Transactions at Stryker

In other news, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares in the company, valued at approximately $36,879,954.90. This trade represents a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 5.50% of the company’s stock.

Stryker Stock Up 0.1 %

Stryker stock opened at $390.90 on Monday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The firm has a market capitalization of $149.02 billion, a price-to-earnings ratio of 50.37, a price-to-earnings-growth ratio of 2.78 and a beta of 0.96. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The stock’s fifty day moving average is $376.68 and its two-hundred day moving average is $363.22.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the company earned $3.46 EPS. Analysts predict that Stryker Co. will post 13.5 EPS for the current fiscal year.

Stryker Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Tuesday, December 31st were given a dividend of $0.84 per share. The ex-dividend date was Tuesday, December 31st. This is an increase from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a yield of 0.86%. Stryker’s dividend payout ratio is 43.30%.

Wall Street Analyst Weigh In

SYK has been the subject of a number of research reports. UBS Group boosted their price objective on Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. Wells Fargo & Company boosted their price objective on Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Piper Sandler reiterated an “overweight” rating and issued a $420.00 price objective (up previously from $380.00) on shares of Stryker in a research note on Wednesday, October 30th. Needham & Company LLC reiterated a “buy” rating and issued a $442.00 price objective on shares of Stryker in a research note on Wednesday, January 29th. Finally, Barclays upped their price target on Stryker from $402.00 to $418.00 and gave the stock an “overweight” rating in a research note on Thursday, October 31st. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $419.37.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.